Dana Investment Advisors Inc. Reduces Stake in Natus Medical Incorporated (BABY)

Dana Investment Advisors Inc. Reduces Stake in Natus Medical Incorporated (BABY)

Dana Investment Advisors Inc. cut its position in Natus Medical Incorporated (NASDAQ:BABY) by 5.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,793 shares of the company’s stock after selling 2,975 shares during the period. Dana Investment Advisors Inc. owned about 0.15% of Natus Medical worth $1,956,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Fiera Capital Corp acquired a new stake in Natus Medical during the second quarter worth approximately $14,075,000. SG Capital Management LLC increased its stake in Natus Medical by 88.6% in the second quarter. SG Capital Management LLC now owns 468,518 shares of the company’s stock worth $17,710,000 after buying an additional 220,097 shares during the last quarter. Neuberger Berman Group LLC increased its stake in Natus Medical by 9.9% in the second quarter. Neuberger Berman Group LLC now owns 1,572,351 shares of the company’s stock worth $59,435,000 after buying an additional 141,770 shares during the last quarter. Henderson Group PLC increased its stake in Natus Medical by 33.6% in the third quarter. Henderson Group PLC now owns 496,295 shares of the company’s stock worth $19,499,000 after buying an additional 124,769 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in Natus Medical by 5.5% in the third quarter. BlackRock Fund Advisors now owns 2,373,784 shares of the company’s stock worth $93,266,000 after buying an additional 123,345 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

Natus Medical Incorporated (NASDAQ:BABY) traded down 0.70% during midday trading on Tuesday, hitting $35.35. 341,084 shares of the stock were exchanged. Natus Medical Incorporated has a one year low of $29.54 and a one year high of $44.39. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of 27.40 and a beta of 1.02. The company has a 50 day moving average price of $36.62 and a 200 day moving average price of $39.16.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, February 1st. The company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by $0.02. Natus Medical had a return on equity of 13.24% and a net margin of 11.11%. The company had revenue of $107.70 million for the quarter, compared to the consensus estimate of $107.58 million. During the same period in the prior year, the company earned $0.51 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Equities analysts anticipate that Natus Medical Incorporated will post $1.79 EPS for the current year.

BABY has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 20th. Off Wall Street started coverage on shares of Natus Medical in a report on Friday, December 16th. They set a “sell” rating on the stock. Finally, Raymond James Financial, Inc. lowered shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Thursday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $45.25.

In other Natus Medical news, insider James B. Hawkins bought 10,000 shares of Natus Medical stock in a transaction dated Friday, December 16th. The shares were bought at an average price of $35.20 per share, with a total value of $352,000.00. Following the purchase, the insider now owns 477,396 shares of the company’s stock, valued at $16,804,339.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.80% of the stock is owned by corporate insiders.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:BABY).

Related posts

Leave a Comment